Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31561634 | 0.82 | ROCK2 (0.38) | CYP19A1CA2P2RY6LMNAMAPT | |
| SCHEMBL31561625 | 0.82 | CHRNB4 (0.44) | MAPTCHRNB4CHRNA3ADRA2APNMT | |
| SCHEMBL28056978 | 0.82 | ESR1 (0.40) | MAPTCHRNB4CHRNA3MTNR1A | |
| SCHEMBL31561633 | 0.82 | ROCK2 (0.38) | CYP19A1CA2LMNACHRNB4CHRNA3 | |
| SCHEMBL31561635 | 0.82 | ROCK2 (0.38) | CYP19A1CA2P2RY6LMNAMAPT | |
| SCHEMBL30937657 | 0.82 | ROCK2 (0.38) | MALT1CYP19A1CA2P2RY6 | |
| SCHEMBL8557409 | 0.78 | NISCH (0.40) | — | |
| SCHEMBL13963767 | 0.75 | MAPT (0.39) | LMNAMAPTHTTMTNR1A | |
| SCHEMBL7204257 | 0.75 | MTNR1A (0.48) | LMNAMAPTHTTCHRNB4CHRNA3 | |
| SCHEMBL8505509 | 0.74 | NPC1 (0.33) | MAPTBLMMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550467-B2 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| CN-101076524-A | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | PHARMACOPEIA DRUG DISCOVERY (US) | 2007-11-21 | — | — | CN | disclosed |
| EP-1807409-A2 | BICYCLIC COMPOUNDS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | Pharmacopeia Drug Discovery, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-7053223-B2 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060111360-A1 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | PHARMACOPEIA DRUG DISCOVERY, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2006044293-A2 | BICYCLIC COMPOUNDS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20040181068-A1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181068-A1 | Inhibitors of farnesyl protein transferase | FNTA, FNTB, ACAT2 | MALT1 2972/4885CYP19A1 3141/4885CA2 4202/4885 |
| US-20060111360-A1 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | MCHR1, MCHR2, MC4R | MALT1 2502/4885CYP19A1 387/4885CA2 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.